Gavin Cull

Dr

  • The University of Western Australia (M503), 35 Stirling Highway,

    6009 Perth

    Australia

  • 76 Citations
  • 5 h-Index
19962019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Gavin Cull is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Fibroblast Growth Factor 7 Medicine & Life Sciences
T-Cell Leukemia Medicine & Life Sciences
Nomograms Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Polyphenols Medicine & Life Sciences
Stem Cell Transplantation Medicine & Life Sciences
Tea Medicine & Life Sciences
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1996 2019

  • 76 Citations
  • 5 h-Index
  • 12 Article
  • 3 Letter
1 Citation (Scopus)

Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement

Chin, C. K., Tsang, E., Mediwake, H., Khair, W., Biccler, J., Hapgood, G., Mollee, P., Nizich, Z., Joske, D., Radeski, D., Cull, G., Villa, D., El-Galaly, T. C. & Cheah, C. Y., 1 Mar 2019, In : British Journal of Haematology. 184, 5, p. 826-828 3 p.

Research output: Contribution to journalLetter

Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia

Kuzich, J. A., Hutchison, A. P., Lim, K. J. C., Smallbone, P., Denning, K., Wright, M. P., Cull, G., Leah, M. F., Joske, D. J. L., Radeski, D. & Purtill, D., Jul 2019, In : LEUKEMIA & LYMPHOMA. 9 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Bromberg, J. E. C., Issa, S., Bakunina, K., Minnema, M. C., Seute, T., Durian, M., Cull, G., Schouten, H. C., Stevens, W. B. C., Zijlstra, J. M., Baars, J. W., Nijland, M., Mason, K. D., Beeker, A., van den Bent, M. J., Beijert, M., Gonzales, M., de Jong, D. & Doorduijn, J. K., 1 Feb 2019, In : The Lancet Oncology. 20, 2, p. 216-228 13 p.

Research output: Contribution to journalArticle

Lymphoma
Methotrexate
Rituximab
Teniposide
Drug Therapy
2 Citations (Scopus)

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Barrientos, J. C., O'Brien, S., Brown, J. R., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C., Mulligan, S., Jaeger, U., Devereux, S., Pocock, C., Robak, T., Schuster, S. J., Schuh, A., Gill, D., Bloor, A., Dearden, C., Moreno, C., Cull, G., Hamblin, M. & 8 othersJones, J. A., Eckert, K., Solman, I. G., Suzuki, S., Hsu, E., James, D. F., Byrd, J. C. & Hillmen, P., Dec 2018, In : Clinical Lymphoma, Myeloma & Leukemia. 18, 12, p. 803-+ 18 p.

Research output: Contribution to journalArticle

Open Access
20 Citations (Scopus)

Early Treatment Intensification With R-ICE And 90Y-Ibritumomab Tiuxetan (Zevalin)-BEAM Stem Cell Transplantation In Patients With High Risk Diffuse Large B-Cell Lymphoma Patients And Positive Interim PET After 4 Cycles Of R-CHOP-14

Hertzberg, M., Gandhi, M. K., Trotman, J., Butcher, B., Taper, J., Johnston, A., Gill, D., Ho, S-J., Cull, G., Fay, K., Chong, G., Grigg, A., Lewis, I. D., Milliken, S., Renwick, W., Hahn, U., Filshie, R., Kannourakis, G., Watson, A-M., Warburton, P. & 5 othersWirth, A., Seymour, J. F. S., Hofman, M. S., Hicks, R. J. & ALLG, Feb 2017, In : Haematologica. 102, 2, p. 356-363 8 p.

Research output: Contribution to journalArticle

Open Access